From $10k to $100k: 3 Stocks With the Potential for Amazing Returns


  • When considering stocks to buy, investors sometimes overlook several with massive growth potential. These three are some of the most attractive, and investors should pay closer attention to them. 
  • Palantir Technologies (PLTR) PLTR is a data analytics software provider used by top organizations worldwide, from the military to pharmaceutical companies. 
  • MercadoLibre (MELI) MercadoLibre is an underrated player in the e-commerce space that has been putting up impressive numbers for some time now. In some investor circles, it is regarded as the “Amazon of Latin America.” 
  • Merck & Co (MRK) Merck belongs to the same group of companies redefining the pharmaceutical space. Its diversity is its biggest strength, as it operates in two industries: pharmaceuticals and animal health. 
Stocks to Buy - From $10k to $100k: 3 Stocks With the Potential for Amazing Returns

Source: Shutterstock

High-cap stocks are usually the headline stealers and attract the most attention from investors looking for stocks to buy. However, there is some upside to investing in lesser-known stocks. This is especially true if you’re interested in generating a massive return on investment. 

When it comes to this, a good strategy is considering the stocks with the most potential. Also consider the industries they play in, and the level of competition within them. 

Each stock in this article fits the above criteria and is doing increasingly well in the market. Because of this, there is reason to believe they could reward their investors with massive returns in no time. From AI to e-commerce and pharma, these three stocks are underrated players in some of the biggest and most lucrative industries. This makes them ideal investment options in the year’s second half. 

Let’s talk more about these stocks and explore the details that make them great options for investors looking for low-cap stocks to buy. 

Stocks to Buy for Amazing Returns: Palantir Technologies (PLTR)

Palantir logo on the smartphone and the company share price on the day of opening the trade October 1, 2020. Palantir valued at $15.8bn in stock market debut. PLTR stock
Source: Ascannio /

Palantir Technologies (NYSE:PLTR) is a software company that specializes in producing AI-powered data analytics products. Its clientele is rich and diverse, ranging from Fortune 500 companies to military agencies. 

Palantir Technologies’ software can be applied to a variety of use cases. For instance, Lowe’s, one of the company’s loyal customers, uses the software to analyze its customer service. Another client, Archer Aviation, uses the software for flight routing and predicting aircraft maintenance. Most recently, Tampa General Hospital has elected to use the AI software for care coordination within its facilities. 

This means that Palantir Technologies is a force to be reckoned with in the AI data analytics space. PLTR is also contributing to efforts to improve other integral sectors, such as healthcare, military defense, and aviation. These factors contribute to its potential to generate massive returns in the market. 

Moreover, the company has been performing well across all metrics lately. According to its recent quarterly report, it is at a 21% year-over-year growth and has received a 17% margin on GAAP net income.

MercadoLibre (MELI)

MercadoLibre (MELI) homepage on a smartphone
Source: rafapress /

Popularly referred to as the “Amazon of Latin America,” MercadoLibre (NYSE:MELI) is another underrated stock that investors should pay more attention to. The e-commerce giant currently operates in over 18 countries in the Latin market, including Brazil, Argentina, and Mexico, and possesses over 100 million active users. 

Like Amazon, MercadoLibre offers a subscription service through which users can get free shipping and access video and music streaming services. Its numbers over the last three years have also been quite impressive. In 2023, it recorded a 37% increase in net revenue, reaching $14.5 billion. 

This year, the company has picked up right where it left off. Its recent quarterly report shows its strong operational performances across Commerce and Fintech. Its current market cap is $85 billion, and it is undoubtedly the biggest e-commerce platform in Latin America. 

Merck & Co (MRK)

A photo of a Merck & Co Inc (MRK) sign outside a building.
Source: Shutterstock

Merck & Co (NYSE:MRK) is an American pharmaceutical company interested in providing treatments for some of the world’s most significant health challenges. Its greatest advantage comes from its diversity as it operates in two major sectors, pharmaceuticals and Animal health. 

The FDA recently granted priority review for Merck & Co’s biggest treatment yet, Keytruda. In addition to chemotherapy, Keytruda will be used as a first-line treatment for patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma. The treatment is expected to reduce the mortality rate by 28%, and sales have already grown by 20%. 
Furthermore, the company continues to perform impressively in the market. Its recently published quarterly report indicates that it saw a 9% increase in total worldwide sales and recorded strong growth in oncology and vaccines.

On the date of publication, Joel Lim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

Joel Lim is a contributor at and a finance content contractor who creates content for several companies like LTSE and Realtor, along with financial publications, including Business Insider, Yahoo Finance, Mises Institution and Foundation for Economic Education.

Article printed from InvestorPlace Media,

©2024 InvestorPlace Media, LLC